Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Takeda Pharmaceutical Co ( (JP:4502) ).
Takeda Pharmaceutical Co announced that an abstract for their Phase 3 study of the drug oveporexton (TAK-861) for narcolepsy type 1 was inadvertently published by the World Sleep Congress. The abstract was quickly removed, and Takeda plans to present the positive results of their Phase 3 studies at the upcoming World Sleep 2025 congress. The studies met all primary and secondary endpoints, highlighting oveporexton’s potential to transform the standard of care for narcolepsy type 1. Takeda does not expect this incident to significantly impact its financial results.
The most recent analyst rating on (JP:4502) stock is a Hold with a Yen4200.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co is a global biopharmaceutical company headquartered in Osaka, Japan, and Cambridge, Massachusetts. The company focuses on developing innovative medicines in areas such as oncology, rare diseases, neuroscience, and gastroenterology.
Average Trading Volume: 3,933,486
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen6823.2B
See more insights into 4502 stock on TipRanks’ Stock Analysis page.